Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 October 2026
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting
NewsVeterinary
Polish is available via eTranslation, the European Commission's machine translation service.
Translate to Polish | Important information about machine translation
CVMP opinions on veterinary medicinal products
The Committee adopted a positive opinion, in exceptional circumstances, for a marketing authorisation for Bovilis Lumpyvax (lumpy skin disease vaccine (live)), for the active immunisation of cattle to reduce clinical signs and viraemia caused by lumpy skin disease virus.
The Committee adopted a positive opinion for a marketing authorisation for Stemyca (equine umbilical cord mesenchymal stem cells), for reduction of clinical signs of non-food-responsive chronic inflammatory enteropathy (CIE) in dogs.
The Committee adopted a positive opinion for a variation for Mirataz (mirtazapine) to update the product information on the basis of new target animal safety data. The SPC and package leaflet were updated to show that the administration of Mirataz at overdose was associated with some of the known adverse events (e.g. erythema and alopecia at the application site).
Re-examinations of marketing authorisations in exceptional circumstances
The Committee adopted a positive opinion on the re-examination of Vaxxitek HVT+IBD+H5, an avian influenza vaccine. The Committee recommended the extension for one year of the validity of the marketing authorisation in exceptional circumstances.
Union referrals and related procedures
The Committee concluded the procedure for Vetmedin 1.5 mg/ml oral solution for dogs (pimobendan). Due to lack of consensus between Member States in the Veterinary Coordination Group for Mutual Recognition and Decentralised Procedures (CMDv) review procedure on grounds of efficacy, the European Commission (EC) had requested clarifications from the Committee under Article 54(8) of Regulation (EU) 2019/6 on a variation to add an indication. The CVMP, having considered the request by the EC and all available data, concluded, by majority, that the benefit-risk balance of Vetmedin 1.5 mg/ml oral solution for dogs for the proposed indication is positive. The CVMP's clarifications will be sent to the EC for its consideration.
Scientific advice
The Committee adopted two scientific advice reports concerning a pharmaceutical and an immunological product, both for Atlantic salmon.
Limited market classifications and eligibility according to Article 23 of Regulation (EU) 2019/6
Following one request, the CVMP classified a product (ATCvet classification: antiparasitic products, insecticides and repellents) for dogs as intended for a limited market and not eligible for authorisation under Article 23 of Regulation (EU) 2019/6.
Pharmacovigilance
The Committee adopted the outcomes of the signal management process for the current month. The signals submitted by marketing authorisation holders are listed, in chronological order, in the IRIS public portal: List of signals from Veterinary Signal Management · IRIS. In order to access the list, the following filter should be applied in the ‘Submission type’ category: ‘Signal management submission’.
More information about the above-mentioned medicines (including their full indications), guidelines, reflection papers, questions and answers and other documents, such as overviews on comments received during consultation, can be found below in “Related content”.